Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth.
The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables.
A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain.
Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction.
First product filing in China
Enoxaparin injection approval received for US market
First ophthalmic product approval received for US market
Fosun Pharma acquires majority stake
First USFDA approval for Penems plant in Hyderabad & Sterile Injectable plant at Pashamylaram, Hyderabad
First USFDA approval for API plant in VSEZ & for API plant in Pharmacity, Visakhapatnam
Dedicated facility for Penems commissioned at Pashamylaram, Hyderabad
Manufacturing lines including Ophthalmic Line and Automated Bag Line added at Dundigal facility
Gland enters Canada with Amiodarone PFS
Enters Europe with Tirofiban
Oncology formulations facility at Visakhapatnam receives USFDA acceptance
Dundigal formulations facility receives UK MHRA and EMEA approvals
Forays into Australia with Azithromycin Injection.
Rocuronium, the first product approval in New Zealand
Introduces Heparin, its flagship product, in the US market
Enters the US market with Ketorolac PFS
Dundigal formulations facility receives USFDA acceptance
Supplies Enoxaparin in Brazil and other semi-regulated markets
Launches Enoxaparin injectionin India
Signs its first Contract Manufacturing agreement for regulated markets
R&D facility set up at Dundigal, Hyderabad
Flagship manufacturing facility at Dundigal becomes operational
Becomes the first company to set up a PFS facility in India, in collaboration with Vetter Pharma, Germany
Becomes a public limited company from a private limited company
PVN Raju founds Gland Pharma to manufacture and market Heparin injection for the domestic market and provides contract manufacturing services for other pharmaceutical companies